Atogepant and Elexacaftor: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Atogepant
Elexacaftor
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased OATP1B1/OATP1B3 substrate exposure
Interaction Deep Dive
Concomitant administration of elexacaftor with drugs that are both OATP1B1 and OATP1B3 substrates may increase the plasma concentrations of OATP1B1/OATP1B3 substrates. When elexacaftor is used concomitantly with OATP1B1/OATP1B3 substrates, use with caution and monitor appropriately1.
Why it happens (mechanism)
Inhibition of OATP1B1-mediated efflux transport by elexacaftor; inhibition of OATP1B3-mediated efflux transport by elexacaftor
Common questions
Can I take Atogepant and Elexacaftor together?
Increased OATP1B1/OATP1B3 substrate exposure Always confirm with your pharmacist or prescriber before making any change.
How serious is the Atogepant and Elexacaftor interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Atogepant or Elexacaftor need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: TRIKAFTA(R) oral tablets oral granules, elexacaftor, tezacaftor, ivacaftor oral tablets oral granules; ivacaftor oral tablets oral granules. Vertex Pharmaceuticals Incorporated (per FDA), Boston, MA, 2024. DailyMed
Keep reading about Atogepant
Keep reading about Elexacaftor
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist